MAPT inhibition has been implicated as one of the potential mechanisms underlying chemotherapy-induced cognitive dysfunction, and it may play a role in the cognitive impairments observed in patients receiving CMF chemotherapy. The gene discussed is MAPT; the disease is Cognitive impairment.